Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Kidney Cancer
  •  Immunotherapy
  •  Brain and Spinal Cord Cancer
  •  General Oncology
  •  Breast Cancer
  •  Stomach Cancer
  •  Thoracic Oncology
  •  Gastrointestinal Cancer


Citation: Clin Oncol. 2022;7(1):1943.DOI: 10.25107/2474-1663.1943

Variations in Radiosensitivity of Breast Cancer and Normal Breast Cell Lines Using a 200 MeV Clinical Proton Beam

Peter du Plessis, Elsie Seane, Xanthene Miles, Shankari Nair, Jacobus Slabbert and Charlot Vandevoorde

Department of Nuclear Medicine, Division of Radiation Biophysics, iThemba LABS (Laboratory for Accelerator Based Sciences), South Africa
Department of Medical Imaging and Therapeutic Sciences, Cape Peninsula University of Technology, South Africa

*Correspondance to: Peter du Plessis 

 PDF  Full Text Research Article | Open Access


Background: Worldwide, proton therapy is increasingly used as a radiation treatment alternative to photon therapy for breast cancer, primarily to decrease the risk for radiation-induced cardiovascular toxicity. However, uncertainties remain on the use of a constant Relative Biological Effectiveness (RBE) of 1.1 in clinical proton therapy. The beam at the position of the entrance plateau was used as the reference radiation in this study to signpost variation in RBEEP.
Objectives: This in vitro study aimed to determine the radiosensitivity of both cancerous and noncancerous breast cells to clinical proton irradiation. The variation in RBE at different depths along the proton Spread-Out Bragg Peak will be investigated.
Methods: Malignant (MCF-7) and non-Malignant (MCF-10A) breast cells were irradiated with doses ranging from 0.5 Gy to 4 Gy at 6 positions: the entrance plateau, 3 points on the Bragg peak (Proximal-, Middle- and Distal-SOBP), the 80% Dmax, and 40% Dmax. A Cytokinesis-Block Micronucleus (CBMN) assay was performed to determine cytogenetic damage using fluorescent
Results: A gradual increase was observed in α parameters with depth for both cell lines. Variations in the RBEEP between 0.99 to 1.99 for the cancerous cells and 0.92 to 1.60 for the non-cancerous breast cells, were observed. In fractionated proton therapy, the MCF-10A cells had a reduced repair in radiation-induced DNA damage between fractions compared to the cancerous MCF-7 cell line.
Conclusion: The RBEEP results showed a clear increase in RBEEP along the proton SOBP. This information could be used by the computational modeling community to further develop biologically motivated treatment planning for proton therapy. In addition, this study reveals a higher radiosensitivity for the non-cancerous breast cells.


Breast cancer; Proton therapy; Cytokinesis-block micronucleus assay; MCF-7 cells; MCF-10A cells; Radiobiology; RBE; Hypofractionation

Cite the Article:

du Plessis P, Seane E, Miles X, Nair S, Slabbert J, Vandevoorde C. Variations in Radiosensitivity of Breast Cancer and Normal Breast Cell Lines Using a 200 MeV Clinical Proton Beam. Clin Oncol. 2022;7:1943..

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Inducing Anti-Tumor Immune Responses in Lung Adenocarcinoma: High-Dose of Ascorbic Acid Combined with Arginine and Magnesium Sulfate
 Abstract  PDF  Full Text
Loss of EAF2 Facilitates Pancreatic Cancer Progression via Inhibiting the Apoptosis of the Neoplastic Cells
 Abstract  PDF  Full Text
View More...